


What is claimed is:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof,



wherein

ring A is selected from 3-8 membered heterocycloalkyl, and the 3-8 membered heterocycloalkyl is optionally substituted with 1, 2 or 3 R;

R₁, R₂, R₃, R₄ and R₅ are each independently selected from H, halogen, OH, NH₂, CN, C₁₋₆ alkyl and C₁₋₆ heteroalkyl, and the C₁₋₆ alkyl and C₁₋₆ heteroalkyl are optionally substituted with 1, 2 or 3 R;

or R₁ and R₂ are connected together to form ring B;

or R₂ and R₃ are connected together to form ring B;

or R₃ and R₄ are connected together to form ring B;

or R₄ and R₅ are connected together to form ring B;

ring B is selected from phenyl, C₅₋₆ cycloalkenyl, 5-6 membered heterocycloalkenyl and 5-6 membered heteroaryl, and the phenyl, C₅₋₆ cycloalkenyl, 5-6 membered heterocycloalkenyl and 5-6 membered heteroaryl are optionally substituted with 1, 2 or 3 R_a;

R_a is selected from halogen, OH, NH₂, CN, C₁₋₆ alkyl and C₁₋₆ heteroalkyl, and the C₁₋₆ alkyl and C₁₋₆ heteroalkyl are optionally substituted with 1, 2 or 3 R;

R₆ is selected from H, halogen and C₁₋₆ alkyl, and the C₁₋₆ alkyl is optionally substituted with 1, 2 or 3 R;

R₇ is selected from 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl and C₅₋₆ cycloalkyl, and ~~the~~ 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl and C₅₋₆ cycloalkyl are optionally substituted with 1, 2 or 3 R;

L is selected from a single bond, -NH-, -S-, -O-, -C(=O)-, -C(=S)-, -CH₂-, -CH(R_b)- and -C(R_b)₂-;

L' is selected from a single bond and -NH-;

R_b is selected from C₁₋₃ alkyl and C₁₋₃ heteroalkyl, and the C₁₋₃ alkyl and C₁₋₃ heteroalkyl are optionally substituted with 1, 2 or 3 R;

R₈ is selected from H, C₁₋₆ alkyl and C₁₋₆ heteroalkyl, and the C₁₋₆ alkyl and C₁₋₆ heteroalkyl are optionally substituted with 1, 2 or 3 R;

R is selected from halogen, OH, NH₂, CN, C₁₋₆ alkyl, C₁₋₆ heteroalkyl and C₃₋₆ membered cycloalkyl, and the C₁₋₆ alkyl, C₁₋₆ heteroalkyl and C₃₋₆ membered cycloalkyl are optionally substituted with 1, 2 or 3 R';

R' is selected from F, Cl, Br, I, OH, NH₂, CN, CH₃, CH₃CH₂, CH₃O, CF₃, CHF₂, CH₂F, cyclopropyl, propyl, isopropyl, N(CH₃)₂ and NH(CH₃);

“hetero” means a heteroatom or a heteroatomic group, the “hetero” in the 3-8 membered heterocycloalkyl, C₁₋₆ heteroalkyl, 5-6 membered heterocycloalkenyl, 5-6 membered heteroaryl, 4-6 membered heterocycloalkyl and C₁₋₃ heteroalkyl is each independently selected from -C(=O)N(R)-, -N(R)-, -NH-, N, -O-, -S-, -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O)-, -S(=O)₂- and -N(R)C(=O)N(R)-;

in any of the cases above, the number of heteroatoms or heteroatomic groups is each independently selected from 1, 2 and 3.

2. The compound or pharmaceutically acceptable salt thereof as defined in claim 1, wherein R is selected from F, Cl, Br, I, OH, NH₂, CN, CH₃, CH₃CH₂, CH₃O, CF₃, CHF₂, CH₂F, cyclopropyl, propyl, isopropyl, N(CH₃)₂, NH(CH₃) and N(CH₂CH₃)₂.

3. The compound or pharmaceutically acceptable salt thereof as defined in claim 1-~~or 2~~, wherein ring A is selected from aziridinyl, azetidiny, pyrrolidinyl, piperidyl, piperazinyl, 1,4-diazacycloheptyl and 3,6-diazabicyclo [3.2.0] heptyl, and the aziridinyl, azetidiny, pyrrolidinyl, piperidyl, piperazinyl, 1,4-diazacycloheptyl and 3,6-diazabicyclo [3.2.0] heptyl are optionally substituted with 1, 2 or 3 R;



or, R₁, R₂, R₃, R₄ and R₅ are each independently selected from H, F, Cl, Br, I, OH, NH₂, CN, CH₃, CH₃CH₂, (CH₃)₂CH, CH₃O, CH₃NH and CH₃NH(C=O)O, and the CH₃, CH₃CH₂, (CH₃)₂CH, CH₃O, CH₃NH and CH₃NH(C=O)O are optionally substituted with 1, 2 or 3 R;

or, ring B is selected from pyrazolyl, imidazolyl, pyrrolyl, thienyl, furyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, triazinyl, morpholinyl, cyclopentenyl and cyclohexenyl, and the pyrazolyl, imidazolyl, pyrrolyl, thienyl, furyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, phenyl, pyridyl, pyrimidinyl, pyridazinyl, triazinyl, morpholinyl, cyclopentenyl and cyclohexenyl are optionally substituted with 1, 2 or 3 R_a;

or, R_a is selected from F, Cl, Br, I, OH, NH₂, CN, CH₃, CH₃CH₂, (CH₃)₂CH, CH₃O and CH₃C(=O);

or, R₆ is selected from H, F, Cl, Br, I and C₁₋₃ alkyl, and the C₁₋₃ alkyl is optionally substituted with 1, 2 or 3 R₇;

~~or, R₈ is selected from H, C₁₋₄ alkyl and C₁₋₄ heteroalkyl, and the C₁₋₄ alkyl and C₁₋₄ heteroalkyl are optionally substituted with 1, 2 or 3 R;~~




4. The compound or pharmaceutically acceptable salt thereof as defined in claim 3, wherein R₁, R₂, R₃, R₄ and R₅ are each independently selected from H, F, Cl, Br, I, OH, NH₂, CN, CH₃, CH₃CH₂, (CH₃)₂CH, CH₃O, CH₃NH, (CH₃)₂N, (CH₃)₂N(C=O)O and CH₃NH(C=O)O;

or, ring B is selected from phenyl, pyrazolyl, 1-methyl-1*H*-pyrazolyl and 1-(1*H*-pyrazole-1-yl)ethanone group;

or, R₆ is selected from H, F, Cl, Br, I, CH₃, CF₃, CHF₂ and CH₂F;

or, R₈ is selected from H, CH₃, CH₃CH₂, (CH₃)₂CHCH₂, (CH₃)₂CH, CH₃O, CH₃NH, (CH₃)₂N, (CH₃)₂NCH₂ and CH₃NHCH₂;



5. The compound or pharmaceutically acceptable salt thereof as defined in claim 1 ~~or 2~~, wherein R₇ is selected from morpholinyl, piperidyl, azetidiny, azacyclopentany, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, cyclohexyl, cyclopentany, phenyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, and the morpholinyl, piperidyl, azetidiny, azacyclopentany, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, cyclohexyl, cyclopentany, phenyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl are optionally substituted with 1, 2 or 3 R.



6. The compound or pharmaceutically acceptable salt thereof as defined in claim 5, wherein R₇ is selected from , , , , , and the , , , , , and are optionally substituted with 1, 2 or 3 R.

7. The compound or pharmaceutically acceptable salt thereof as defined in claim 6, wherein R₇ is selected from , , , , , , , , , , , , , , , , and .



8. The compound or pharmaceutically acceptable salt thereof as defined in claim 1 or 2, wherein R_8 is selected from H, C_{1-4} alkyl and C_{1-4} heteroalkyl, and the C_{1-4} alkyl and C_{1-4} heteroalkyl are optionally substituted with 1, 2 or 3 R.

9. The compound or pharmaceutically acceptable salt thereof as defined in claim 8, wherein R_8 is selected from H, CH_3 , CH_3CH_2 , $(CH_3)_2CHCH_2$, $(CH_3)_2CH$, CH_3O , CH_3NH , $(CH_3)_2N$, $(CH_3)_2NCH_2$ and CH_3NHCH_2 .

10. The compound or pharmaceutically acceptable salt thereof as defined in claim





11. The compound or pharmaceutically acceptable salt thereof as defined in claim



12. The compound or pharmaceutically acceptable salt thereof as defined in claim







and wherein ~~L is as defined in claim 1,~~₂

~~R₁, R₂, R₄, R₅, R₆, R₇, and R₈~~_{R₅} are as defined in claim 1 ~~or 3,~~


~~R₆ is as defined in claim 1 or 3,~~

~~R₇ is as defined in claim 1, 5, 6 or 7,~~

~~R₈ is as defined in claim 1, 3 or 4,~~


~~R₉ is selected from H and C₁₋₃ alkyl~~_{as defined in claim 3.}

~~1015.~~ The compound or pharmaceutically acceptable salt thereof as defined in claim ~~149,~~ selected from




and wherein R₁, R₂, R₄, R₅, R₆, R₇, R₈, R₉ and L are as defined in claim ~~9, and ring~~
~~B is as defined in claim 1 or 3~~_{14.}


~~1116.~~ The compound or pharmaceutically acceptable salt thereof as defined in claim ~~1015,~~ selected from




and wherein R₁, R₂, R₄, R₅, R₆, R₇, R₈, L, R₉ and R_a are as defined in claim 1540.

1217. A compound of the following formula or a pharmaceutically acceptable salt thereof, selected from





1318. The compound or pharmaceutically acceptable salt thereof as defined in claim 1317, selected from



14. ~~The compound or pharmaceutically acceptable salt thereof as defined in any one of claims 1 to 13 for use as a medicine for treating cancer.~~

15. ~~Use of the compound or pharmaceutically acceptable salt thereof for use as defined in claim 1 in the manufacture of a medicament for the treatment of cancer~~4, wherein the cancer is lung cancer, lymphoma, esophageal cancer, ovarian cancer, pancreatic cancer, rectal cancer, glioma, cervical cancer, urothelial cancer, gastric cancer, endometrial cancer, liver cancer, cholangiocarcinoma, breast cancer, colon cancer, leukemia or melanoma.